XML 120 R92.htm IDEA: XBRL DOCUMENT
v3.22.1

Operating Income - Additional Information (Details) € in Thousands | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Dec. 31, 2021 EUR (€) | Dec. 31, 2021 USD ($) bond | Dec. 31, 2021 EUR (€) bond | Dec. 31, 2020 USD ($) | Dec. 31, 2020 EUR (€) | Dec. 31, 2019 USD ($) bond | Dec. 31, 2019 EUR (€) bond | Dec. 31, 2020 EUR (€) | Dec. 31, 2019 EUR (€)
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Total operating income |  |  | € 85,579 |  | € 7,758 |  | € 40,961 |  |
Industrial income recognized |  |  | 80,069 |  | 765 |  | 30,839 |  |
Revenue |  |  | 85,579 |  | 7,758 |  | 40,961 |  |
Research tax credit (CIR) |  |  | 5,510 |  | 6,993 |  | 10,122 |  |
Research tax credit | € 5,282 |  | 5,282 | $ 9,585,000 |  | $ 8,785,000 |  | € 7,911 | € 9,585
Expense relating to resolution of dispute |  |  | 1,892 |  |  |  |  |  |
Exchange gains on trade receivables |  |  | € 223 |  | 968 |  | € 1,992 |  |
Genfit | Ipsen |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Proportion of ownership interest in associate (as a percent) |  | 8.00% | 8.00% |  |  |  |  |  |
Terns Pharmaceuticals |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Total operating income | $ |  | $ 0 |  | 0 |  | 34,900,000 |  |  |
Non-refundable upfront payment | $ |  |  |  |  |  | 35,000,000 |  |  |
Development and commercial milestones payments recognized | $ |  |  |  |  |  | 0 |  |  |
Revenue | $ |  | 0 |  | 0 |  | 34,900,000 |  |  |
Deferred upfront payment | $ |  |  |  |  |  | $ 100,000 |  |  |
Royalties on commercial sales recognized | $ |  | 0 |  |  |  |  |  |  |
Revenue on supply of drug product recognized | $ |  | 0 |  |  |  |  |  |  |
Terns Pharmaceuticals | Performance obligations satisfied over time |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Number of Performance Obligations | bond |  |  |  |  |  | 3 | 3 |  |
Terns Pharmaceuticals | Maximum |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Development and commercial milestones payments recognized | $ |  | $ 0 |  | 0 |  | $ 193,000,000 |  |  |
Royalties on commercial sales recognized | $ |  |  |  | $ 0 |  | $ 0 |  |  |
CIR tax credit |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Research tax credit (CIR) |  |  | € 5,282 |  | € 6,020 |  | € 8,125 |  |
Ipsen |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Licence fee income | 80,000 |  |  |  |  |  |  |  |
Deferred income | € 40,000 |  | 40,000 |  |  |  |  |  |
Sale price, clinical trial phase |  |  | € 40,000 |  |  |  |  |  |
Ipsen | Performance obligations satisfied over time |  |  |  |  |  |  |  |  |
Disclosure Of Other Income [Line Items] |  |  |  |  |  |  |  |  |
Number of Performance Obligations | bond |  | 4 | 4 |  |  |  |  |  |

X
- Definition Deferred upfront payment. + References No definition available. + Details
Name: | gnft_DeferredUpfrontPayment
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development and commercial milestones payments recognized. + References No definition available. + Details
Name: | gnft_DevelopmentAndCommercialMilestonesPaymentsRecognized
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of other income. + References No definition available. + Details
Name: | gnft_DisclosureOfOtherIncomeLineItems
Namespace Prefix: | gnft_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expense Relating To Resolution Of Dispute + References No definition available. + Details
Name: | gnft_ExpenseRelatingToResolutionOfDispute
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable upfront payment. + References No definition available. + Details
Name: | gnft_NonRefundableUpfrontPayment
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research tax credit. + References No definition available. + Details
Name: | gnft_ResearchTaxCredit
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue From Contracts With Customers, Number Of Performance Obligations + References No definition available. + Details
Name: | gnft_RevenueFromContractsWithCustomersNumberOfPerformanceObligations
Namespace Prefix: | gnft_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue on supply of drug product recognized. + References No definition available. + Details
Name: | gnft_RevenueOnSupplyOfDrugProductRecognized
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties on commercial sales recognized. + References No definition available. + Details
Name: | gnft_RoyaltiesOnCommercialSalesRecognized
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sale Price, Clinical Trial Phase + References No definition available. + Details
Name: | gnft_SalePriceClinicalTrialPhase
Namespace Prefix: | gnft_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of current contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 105 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_CurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 91 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of income arising from licence fees. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_LicenceFeeIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of operating income that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 26 -IssueDate 2021-01-01 -Paragraph 35 -Subparagraph b -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 103 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 102 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_OtherIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2021-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2021-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 28 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 23 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 32 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard -URIDate 2021-03-24 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 33 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard -URIDate 2021-03-24 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 34 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard -URIDate 2021-03-24 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 82 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard -URIDate 2021-03-24 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 103 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard -URIDate 2021-03-24 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 102 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard -URIDate 2021-03-24 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2021-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2021-03-24 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2021-03-24 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph B10 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue arising from the rendering of services. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueFromRenderingOfServices
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_OwnershipAxis=gnft_GenfitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gnft_IpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=gnft_TernsPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=gnft_CIRTaxCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gnft_IpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |